Patents by Inventor Andrzej Chruscinski

Andrzej Chruscinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR PREDICTING TOLERANCE IN TRANSPLANT PATIENTS
    Publication number: 20240167095
    Abstract: Provided herein is a method of predicting operational tolerance in a transplant patent and/or identifying a transplant patient as a candidate for reducing the dosage of immunosuppressant, comprising determining the ratio of the expression level of an anti-inflammatory gene to the expression level of a pro-inflammatory gene in PBMCs from the patient. The method can further comprise determining the ratio in a sample of the graft of the patient. Also provided is a kit that can be used to practice the methods disclosed herein.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 23, 2024
    Inventors: Gary Levy, Andrzej Chruscinski, Stephen Juvet
  • FGL2 antibodies and binding fragments thereof and uses thereof
    Patent number: 11325969
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: May 10, 2022
    Assignee: Veritas Therapeutics Inc.
    Inventors: Gary Levy, Ramzi Khattar, Andrzej Chruscinski, Barbara Vanderhyden, Curtis McCloskey
  • FGL2 ANTIBODIES AND BINDING FRAGMENTS THEREOF AND USES THEREOF
    Publication number: 20200190176
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.
    Type: Application
    Filed: May 3, 2018
    Publication date: June 18, 2020
    Inventors: Gary Levy, Ramzi Khattar, Andrzej Chruscinski, Barbara Vanderhyden, Curtis McCloskey
  • FGL2 Expressing Regulatory T Cells
    Publication number: 20170258834
    Abstract: This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory T cells (Treg) and associated compositions for the induction of immune tolerance are described. The methods and uses may be used to prevent transplant rejection, and in the treatment of diseases or conditions such as graft versus host disease, autoimmune disease and allergies. Also provided are transgenic mice that ubiquitously express FGL2 protein from which the Treg may be isolated.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 14, 2017
    Applicant: Veritas Therapeutics Inc.
    Inventors: Gary A. Levy, David Grant, Andrzej Chruscinski